Leukemia News and Research RSS Feed - Leukemia News and Research

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis. [More]
MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

Bacillus anthracis bacteria have very efficient machinery for injecting toxic proteins into cells, leading to the potentially deadly infection known as anthrax. A team of MIT researchers has now hijacked that delivery system for a different purpose: administering cancer drugs. [More]
Scientists discover new clues about drug used in treating blood cancer

Scientists discover new clues about drug used in treating blood cancer

Keck Medicine of USC scientists have discovered new clues about a drug instrumental in treating a certain blood cancer that may provide important targets for researchers searching for cures. [More]
BRD4 protein appears to play key role in keeping stem cells in immature "pluripotent" state

BRD4 protein appears to play key role in keeping stem cells in immature "pluripotent" state

A protein implicated in several cancers appears to play a pivotal role in keeping stem cells in an immature "pluripotent" state, according to a new study by NYU Langone Medical Center scientists. [More]
Novel treatment makes life-saving difference to young patients with Ph-like ALL

Novel treatment makes life-saving difference to young patients with Ph-like ALL

St. Jude Children's Research Hospital investigators found that adjusting treatment based on early response to chemotherapy made a life-saving difference to young patients with an acute lymphoblastic leukemia (ALL) subtype associated with a poor outcome. [More]
Eutropics inks NCI contract to develop Praedicare Dx platform technology for AML treatments

Eutropics inks NCI contract to develop Praedicare Dx platform technology for AML treatments

EUTROPICS Inc., a privately held company developing novel diagnostic tests, today announced that it has signed a contract with the National Cancer Institute through the Small Business Initiative Research (NCI-SBIR) program to develop its' Praedicare Dx platform for personalized medicine approaches in Acute Myeloid Leukemia (AML) patient management. [More]
Scientists identify gene mutation that causes aplastic anemia

Scientists identify gene mutation that causes aplastic anemia

An international team of scientists has identified a gene mutation that causes aplastic anemia, a serious blood disorder in which the bone marrow fails to produce normal amounts of blood cells. [More]
Amgen seeks FDA approval for leukemia drug blinatumomab

Amgen seeks FDA approval for leukemia drug blinatumomab

Amgen today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab. [More]
Researchers discover new molecule that allows for multiplication of stem cells in cord blood

Researchers discover new molecule that allows for multiplication of stem cells in cord blood

Investigators from the Institute for Research in Immunology and Cancer at the Université de Montréal have just published, in the prestigious magazine Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. [More]
Dominica Anderson named recipient of 2014 Julie and Ben Rogers Award for Excellence in Patient Care

Dominica Anderson named recipient of 2014 Julie and Ben Rogers Award for Excellence in Patient Care

Dominica Anderson, a nursing assistant at The University of Texas MD Anderson Cancer Center, is the 2014 recipient of the Julie and Ben Rogers Award for Excellence in Patient Care. [More]
UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
Complete analysis of the global stem cell market

Complete analysis of the global stem cell market

BCC Research reveals in its new report, THE GLOBAL MARKET FOR STEM CELLS, the global market for stem cells is expected to grow to nearly $10.6 billion by 2018, with a five-year compound annual growth rate (CAGR) of 13.6%. [More]
Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. [More]
Agents targeting mitochondrial metabolism can have activity in leukemia

Agents targeting mitochondrial metabolism can have activity in leukemia

Results of a Phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy. [More]
Scientists identify how immune cells use two critical receptors to clear dead cells from the body

Scientists identify how immune cells use two critical receptors to clear dead cells from the body

In most of the tissues of the body, specialized immune cells are entrusted with the task of engulfing the billions of dead cells that are generated every day. [More]
New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology. [More]
Longer looks: Alzheimer's and a marriage; racism in medicine; abortion restrictions in Texas

Longer looks: Alzheimer's and a marriage; racism in medicine; abortion restrictions in Texas

The US, which has a mostly private health-care system, manages to spend more on its public health-care system than countries where the health-care system is almost entirely public. America's government spends more, as a percentage of the economy, on public health care than Canada, the United Kingdom, Japan or Australia. And then it spends even more than that on private health care. [More]
Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine (CIRM) and Celgene Corporation, a New Jersey-based biopharmaceutical company, have launched a phase 1 human clinical trial to assess the safety and efficacy of a novel monoclonal antibody for patients with chronic lymphocytic leukemia (CLL). [More]

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Infinity Pharmaceuticals, Inc. and AbbVie Inc. today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer. [More]